TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06003972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copaxone
Description: Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guideline directed medical therapy (GDMT)
Description: GDMT for heart failure according to the AHA guidelines.
Study: NCT05000073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis and socio-aesthetic care
Description: dialysis and socio-aesthetic care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dialysis
Description: dialysis
Study: NCT05595213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist cooling device with cooling plate
Description: This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist cooling device with cooling plate
Description: This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
Study: NCT02009254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Study: NCT05390411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOCIAL HF
Description: participate in SOCIAL HF training
Study: NCT05595213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist fan activating device without cooling plate
Description: This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist fan activating device without cooling plate
Description: This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Flash Diary
Description: Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Flash Diary
Description: Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
Study: NCT06066320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMST
Description: Participants randomised to the MMST group will complete the computer based paced auditory serial addition task (PASAT-C) in the presence of one observer and is informed that incorrect answers result in reduced monetary compensation. Simultaneously, the participant is exposed to emotionally evocative images and white noise via headphones

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TSST
Description: Participants randomly assigned to the TSST condition will be exposed to a traditional TSST protocol. The TSST consists of a preparation phase (5 min), followed by a mock job interview and a mental arithmetic task (5 min each) in front of a panel consisting of two observers and a video recording device.
Study: NCT05650697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 1 cannabidiol (CBD) oil with silicone ointment
Description: CBD oil with silicone ointment will be used on either the top half of a forehead scar. Specific placement instructions will be given to the participant. They will treat the scar the same way for 7 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 2 cannabidiol (CBD) oil with silicone ointment
Description: CBD oil with silicone ointment will be used on either the bottom half of a forehead scar. Specific placement instructions will be given to the participant. They will treat the scar the same way for 7 months.
Study: NCT05955248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed-nutriend supplement (NUT)
Description: Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed-nutriend supplement (NUT)
Description: Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Prehabilitation (MM)
Description: Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control (CTRL)
Description: Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
Study: NCT05925179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical crown lengthening
Description: Surgical clinical crown lengthening with bone excision

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical crown lengthening
Description: Surgical clinical crown lengthening with bone excision
Study: NCT05900596

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal blood sampling
Description: Fetal scalp blood sampling and analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal blood sampling
Description: Fetal scalp blood sampling and analysis
Study: NCT04579107

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Contrast Enhanced Mammography
Description: A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
Study: NCT05925179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin
Description: Pre-operative antibiotic prophylaxis (2 g Augmentin)
Study: NCT05251467

Intervention type: OTHER
Intervention: Focus group
Description: Focus group to confirm PROM conceptual framework

Intervention type: OTHER
Intervention: Patient interview (n = approximately 10)
Description: Patient interviews to refine possible questions for the PROM

Intervention type: OTHER
Intervention: Questionnaire (n = 180)
Description: Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population

Intervention type: DEVICE
Intervention: Testing of the pilot PROM in a smartphone app (n = 150)
Description: Daily testing of the pilot PROM in a smartphone app for 2 weeks
Study: NCT05695378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Description: Subjects will receive KM-819 400 mg orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Description: Subjects will receive KM-819 400 mg orally daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo orally daily.
Study: NCT04728633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized Oil
Description: Given via infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Given gelatin sponge via injection
Study: NCT05380180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OneClick Social Engagement Intervention
Description: Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.

Intervention type: OTHER
Group type: OTHER
Intervention: OneClick Social Engagement Intervention Extension
Description: Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
Study: NCT06224413

Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study: NCT05855707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WJ-MSC infusion
Description: cellular therapy
Study: NCT05669274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk containing A1 and A2 beta-casein
Description: Milk dose for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk containing only A2 beta-casein
Description: Milk dose for 2 weeks
Study: NCT05393440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BS-006
Description: BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BS-006
Description: BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
Study: NCT04647188

Intervention type: OTHER
Intervention: Robotic assisted surgery with IDR data capture
Description: Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology

Intervention type: OTHER
Intervention: Robotic assisted surgery with IDR data capture
Description: Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology

Intervention type: OTHER
Intervention: Robotic assisted surgery with IDR data capture
Description: Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology

Intervention type: OTHER
Intervention: Robotic assisted surgery with IDR data capture
Description: Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology

Intervention type: OTHER
Intervention: Robotic assisted surgery with IDR data capture
Description: Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology

Intervention type: OTHER
Intervention: Robotic assisted surgery with IDR data capture
Description: Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
Study: NCT06105268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flipped learning training group
Description: flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
Study: NCT06029348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Task
Description: Study volunteers will be asked to complete a 4-minute Paced Auditory Serial Addition Task, which is a standardized task that is widely used to study cardiovascular responses to acute psychological challenges (or stressors) in a laboratory setting.
Study: NCT06422819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate variability Biofeedback [HRV-BFB]
Description: Biofeedback (BFB), sometimes referred to as biological feedback technique, is a non-invasive and non-pharmacological approach based on physiological recordings that provide real-time feedback enabling people to learn how to control their physiological processes, which are typically unconscious and beyond their control. HRV-BFB specifically targets heart rate variability (HRV), which can help regulate the autonomic nervous system (including vagal tone and sympathetic-parasympathetic balance) as well as emotional states. HRV-BFB has been clinically and experimentally validated as a physiological intervention and has demonstrated its effectiveness. However, it has never been studied in an adult FND population.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pseudo HRV-BFB
Description: The pseudo HRV-BFB intervention aims to implement the same HRV BFB methods with no specific effect on HRV.
Study: NCT05806580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.
Study: NCT05927935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised strength exercise intervention
Description: A 6 months exercise intervention of training 2 times a week. Patients will be instructed by a physiotherapist during the first session, in order to be able to perform the exercises at home or in a local gymnasium based on personal preference. Subsequently, there are supervised sessions once every second week (12 sessions in total). The intervention will consist of 6 exercises. 4 targeting planes of hip movement (i.e., flexion, extension, abduction and adduction), a general lower extremity- and a trunk exercise. Progression is made when an exercise is performed with the designated number of sets and repetitions, with good performance quality and tolerable pain. Progression is provided by 3 levels of difficulty and secondly by the number of repetitions or where possible by increasing the external load. In addition, patient information and education is identical to what is delivered in the usual care group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal educational intervention (usual care)
Description: Usual care varies slightly across regions in Denmark and between Denmark and Australia. The consensus is that the patient should be advised to remain physically active and reduce symptom provoking activities. Therefore, patients will receive a referral for physiotherapy and supplementary a minimal educational intervention is provided as usual care. Patients allocated to the usual care group will receive written information on self-management of hip symptoms including advice about staying physically active in accordance with the World Health Organization guidelines on physical activity and sedentary behavior. Moreover, self-management of hip symptoms will include advice to reduce symptoms by focusing on symptom-lowering activities and sports. The content of the information provided as usual care will be identical to the information provided to the patients in the intervention group. Patients in the usual care group can continue to seek any additional treatment they would like.
Study: NCT05919186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmbryORP®
Description: EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmbryORP®
Description: EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmbryORP®
Description: EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmbryORP®
Description: EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 tension 20%
Description: After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 tension 20%
Description: After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 tension 5%
Description: After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 tension 5%
Description: After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
Study: NCT05176535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FertyBiotic Balance
Description: Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
Study: NCT06035016

Intervention type: DRUG
Intervention: pyrotinib combined with Capecitabine
Description: Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w

Intervention type: DRUG
Intervention: treatment of physician's choice
Description: Treatment of physician's choice
Study: NCT05361668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomized: 40 mg Paltusotine
Description: Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomized: 80 mg Paltusotine
Description: Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
Study: NCT06508190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: free walking exercise and continuous positive airway pressure
Description: patients will receive continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night. Also, patients will perform walking exercise for 30 mint, daily for 12 weeks
Study: NCT06473740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)
Description: The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection.
Study: NCT05618977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dramatization simulation
Description: Ethical attitudes of nursing students will be evaluated with dramatization simulation application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-class case studies
Description: In-class case studies will be conducted with the control group students.
Study: NCT05798767

Intervention type: BEHAVIORAL
Intervention: Neuropsychological tests
Description: Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium.

Intervention type: BEHAVIORAL
Intervention: Neuropsychological tests
Description: Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium.